Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Elekta AB (publ)
  6. News
  7. Summary
    EKTA B   SE0000163628


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Elekta : radiotherapy system designed for changing cancer landscape now available for U.S. patients

06/17/2021 | 01:31am EDT

Elekta Harmony linear accelerator cleared by U.S. Food and Drug Administration

ATLANTA, June 17, 2021 - Elekta (EKTA-B.ST) announced today that its Elekta Harmony* radiation therapy system recently received U.S. FDA 510(k) clearance, paving the way for U.S. clinics to harness the system to treat a comprehensive range of indications using the latest radiotherapy techniques. Harmony perfectly balances productivity and precision without compromise, making the system well-suited to address changing U.S. demographics and practice patterns.

"The cancer burden in the United States and worldwide is increasing significantly, arising not just from an aging population, but also from delayed diagnoses and treatments due to Covid-19," notes Larry Biscotti, Elekta's Executive Vice President Region North & Central America. "Harmony was designed not only to enable the latest advanced radiotherapy techniques, but also to simplify and streamline the radiotherapy process, with guided workflows and a user interface that facilitates a short learning curve. The interface gives the treatment staff all the information they need where they need it. The results are shorter treatment times, greater productivity and more patients treated."

"Research results are pointing to the clinical value of hypofractionation for a variety of malignancies, including prostate, breast, and lung cancers," adds John Christodouleas, MD, MPH, SVP of Medical Affairs & Clinical Research Linac-Based RT. "The trends in patterns of care data suggest that hypofractionation - enabled through systems capable of stereotactic body radiotherapy [SBRT] - is going to be routine at all radiotherapy centers," he says. "If only 10 percent of metastatic carcinoma patients are treated with SBRT once or twice throughout their treatment course, SBRT will be in considerable demand. When we designed Harmony, SBRT indications were a priority."

A versatile system that can operate effectively in highly distributed, suburb-based radiotherapy clinics that are part of a larger network is also valuable, Christodouleas says.

"In cancer care, we're seeing a shift in which networks are siting many machines to cover large geographic areas to bring treatment closer to where people live," he observes. "These networks need delivery systems that can handle both technically demanding treatments like SBRT and also more conventional IGRT regimens. Harmony was built as an efficient, versatile linear accelerator allowing clinicians to treat more patients with high-quality precision radiation therapy."

Harmony will provide enhanced:

  • Productivity: the new FastTrack in-room experience reduces patient setup time by as much as 50 percent.** Combined with further workflow enhancements, treatment slots can be reduced by up to 25 percent**, enabling clinicians to deliver high-quality cancer care to more patients.
  • Precision: a best-in-class multi-leaf collimator provides one-millimeter resolution beam-shaping across the full 40 cm X 40 cm field size, which provides "shrink-wrapped" sub-millimeter conformality around the tumor target.
  • Versatility: the option of multiple energies, treatment techniques and imaging modalities, providing the versatility needed to treat the most common indications, including breast, lung, pelvic and head-and-neck cancers.

To register for the launch event, visit: https://findyourbalance.elekta.com/us/.

*Elekta Harmony has CE mark and U.S. FDA 510(k) clearance. Not available in all markets.
**Data maintained internally

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.






(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about ELEKTA AB (PUBL)
07/23ELEKTA : Secures Orders for Brachytherapy Afterloader System
07/23ELEKTA : GenesisCare extends U.S. brachytherapy service with 27 Elekta Flexitron..
07/23ELEKTA : Data from 14 leading cancer centers presented at AAPM highlight global ..
07/21ELEKTA : Notice to the Annual General Meeting of Elekta AB (publ)
07/21Elekta AB Proposes Dividend
07/09ELEKTA : Annual Report for 2020/21 available
07/07Elekta Optimizes Treatment Times for Cancer Patients Via Proactive Service In..
07/07ELEKTA : optimizes treatment times for cancer patients via proactive service inn..
06/17ELEKTA : radiotherapy system designed for changing cancer landscape now availabl..
06/17Elekta AB's Elekta Harmony Radiation Therapy System Receives U.S. FDA 510(K) ..
More news
Sales 2022 15 195 M 1 749 M 1 749 M
Net income 2022 1 543 M 178 M 178 M
Net Debt 2022 395 M 45,4 M 45,4 M
P/E ratio 2022 32,2x
Yield 2022 1,61%
Capitalization 49 327 M 5 682 M 5 678 M
EV / Sales 2022 3,27x
EV / Sales 2023 3,04x
Nbr of Employees 4 276
Free-Float 93,8%
Duration : Period :
Elekta AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELEKTA AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 15
Last Close Price 129,10 SEK
Average target price 120,15 SEK
Spread / Average Target -6,93%
EPS Revisions
Managers and Directors
Gustaf Salford President & Chief Executive Officer
John Adebäck Chief Financial Officer & Group Treasurer
Laurent Leksell Chairman
Steven Mark Wort Chief Operating Officer
Caroline Mofors Chief Compliance & Integrity Office, Senior VP
Sector and Competitors